Mycenax Biotech and RIN Ink Licensing Agreement for ADC Advancement Mycenax Biotech Inc. and Japan's RIN Institute have signed a licensing agreement to utilize RIN's proprietary linker technology for ADC development, enhancing therapeutic solutions.

Mycenax Biotech and RIN Ink Licensing Agreement for ADC Advancement #Taiwan #Taipei #ADC #Mycenax_Biotech #RIN_Institute

Mycenax Biotech Partners with RIN Institute to Advance ADC Development with Innovative Linker Technology Mycenax Biotech has signed a licensing agreement with RIN Institute to utilize its proprietary linker technology. This partnership aims to accelerate ADC development and offers enhanced therapeutic solutions.

Mycenax Biotech Partners with RIN Institute to Advance ADC Development with Innovative Linker Technology #Taiwan #Taipei #ADC_Development #Mycenax_Biotech #RIN_Institute

Mycenax Biotech Partners with RIN to Enhance ADC Development Using Advanced Linker Technology Mycenax Biotech Inc. and Japan's RIN Institute team up through a license agreement to utilize innovative linker technology for developing advanced ADCs.

Mycenax Biotech Partners with RIN to Enhance ADC Development Using Advanced Linker Technology #Taiwan #Taipei #ADC_Development #Mycenax_Biotech #RIN_Institute